Another interesting study is, -Pemetrexed as Second-Line Treatment in Malignant Pleural Mesothelioma after Platinum-Based First-Line Treatment- by Srensen, Jens Benn MD, DMSc, MPA; Sundstrm, Stein MD, DMS; Perell, Katharina MD; Thielsen, Anne-Kathrine MD – Journal of Thoracic Oncology: February 2007 – Volume 2 – Issue 2 – pp 147-152. Here’s an excerpt: -Abstract – Introduction: Pemetrexed is active as first-line therapy for malignant pleural mesothelioma. The target would be to evaluate its activity as second-line treatment. Methods: Patients had disease growth of malignant pleural mesothelioma after previous platinum-based regimens without pemetrexed. Treatment was pemetrexed alone or pemetrexed combined with carboplatin. Pemetrexed dosing was 500 mg/m2 and carboplatin was AUC (area inside of the curve) 5 once every Three weeks.
Results: Thirty-nine patients were included: 28 Danish patients received pemetrexed (three patients received pemetrexed as third-line treatment), whereas 11 Norwegian patients received pemetrexed plus carboplatin. Most sufferers were men (90%), had epithelial subtype (85%), and International Mesothelioma Interest Group stages III to IV (77%). Median age was 62 years (range, 30-77). The median variety of treatment courses was six (range, 1-23). Common Toxicity Criteria grade 3 or 4 toxicity occurred simply respect to leukocytopenia (pemetrexed: 14% of patients; pemetrexed plus carboplatin: 9%) and thrombocytopenia (pemetrexed: 7%; pemetrexed plus carboplatin: 18%). One patient receiving pemetrexed died of sepsis. Partial response rates were 21% and 18%, the median enough time to progression was 21 weeks (range, 4-92) and 32 weeks (range, 4-128+), as well as the median survival was 42 weeks (range, 4-99) and 39 weeks (range, 10-128+) with pemetrexed and pemetrexed plus carboplatin, respectively.
Conclusions: Pemetrexed was generally well tolerated with noteworthy activity in malignant pleural mesothelioma after previous platinum-based treatment and may be considered for second-line treatment.
Another interesting study is termed, -The cytologic decides mesothelioma.- By Ehya H. – Semin Diagn Pathol. 1986 Aug;3(3):196-203. Is an excerpt: -Abstract – The cytologic popular features of malignant mesothelioma cells in serous effusions are presented. Carcinomatous mesotheliomas are seen as a abundant neoplastic cells occurring singly and clusters. The optically dense cytoplasm with lacy peripheral vacuoles, scalloped borders of cell clusters, intercellular spaces, “cell-in-cell” arrangement, and frequent multinucleation of cells are options that come with malignant mesothelioma, but none of them is pathognomonic of the tumor. A beneficial cytoplasmic staining of tumor cells with periodic acid-Schiff (PAS) after diastase digestion, and having mucicarmine stain after hyaluronidase treatment are contrary to the proper diagnosis of mesothelioma, while positive staining with alcian blue, which becomes negative once the treatment with hyaluronidase is strongly suggestive of mesothelioma. The tumor cells react with antibodies to cytokeratin and vimentin, and don’t react with carcinoembryonic antigen. Ultrastructurally, mesothelioma cells are described as long slender branching microvilli and various pinocytotic vesicles. They lack mucin vacuoles and intracellular lumens. A detailed diagnosing mesothelioma is dependent upon a whole information about the clinical historical background and radiologic findings, and proper implementing histochemical, immunodiagnostic, and electron microscopic techniques.-
Another interesting study is termed, -Analysis of acid hyaluronic from the diagnosis of malignant Mesothelioma- by Brian Chiu MD, Andrew Churg MD, Anders Tengblad PHD, Richard Pearce PHD, W. T. E. McCaughey MD – Cancer Volume 54, Issue 10, pages 2195-2199, 15 November 1984. Here is an excerpt: -Abstract – Employing a modified papain digestion cetylpyridinium salt precipitation method, glycosaminoglycans were isolated from 21 mesotheliomas, 34 primary lung carcinomas, 12 carcinomas of other sites, and 7 soft tissue sarcomas. Qualitatively, hyaluronic acid (HA) was present in 20 of 21 mesotheliomas, half from the primary lung adenocarcinomas, and all of the soft tissue sarcomas. Over the average, HA constituted 45% on the total glycosaminoglycans inside the mesotheliomas and 28% in the total from the lung cancers. Quantitatively, mesotheliomas contained statistically larger amounts (mean value, 0.74 mg/g) of HA than primary lung adenocarcinomas (mean value, 0.08 mg/g), but weren’t statistically totally different from soft tissue sarcomas (mean value, 2.01 mg/g) or primary ovarian serous neoplasms (mean value, 0.92 mg/g). Case study concludes that, regardless of previous reports, HA is neither the sole nor the predominant glycosaminoglycan generally in most mesotheliomas, but, considering the proper clinical and histologic setting, the finding of sufficiently high levels (above 0.4 mg/g dry tissue extract) props up the diagnosing mesothelioma if your alternative diagnosis is primary adenocarcinoma of lung.-
The majority of us owe a debt of gratitude about bat roosting fine researchers. If you found many of these excerpts interesting, please browse the studies on their entirety.
Monty Wrobleski is a author of this article. To read more please choose the following links
Depuy Hip Recall Lawsuit
Depuy Hip Recall Florida
Related Articles – Exposure to asbestos, Mesothelioma Cancer, asbestos attorney, lawyer, class action lawyers, suit, suite, lawyer, lawyers, litigation, Treatment, ,
Email this short article into a Friend!
Receive Articles like this one direct in your email box!Subscribe for free today!
No comments:
Post a Comment